The Use Of Nicotinic Acid In The Treatment Of Heart Disease

The Use Of Nicotinic Acid In The Treatment Of Heart Disease.
Combining the vitamin niacin with a cholesterol-lowering statin narcotic appears to provide patients no sake and may also increase side effects, a new study indicates. It's a sad result from the largest-ever study of niacin for heart patients, which involved almost 26000 people canadian accutane. In the study, patients who added the B-vitamin to the statin medicine Zocor saw no added promote in terms of reductions in heart-related death, non-fatal heart attack, stroke, or the need for angioplasty or ignore surgeries.

The study also found that people taking niacin had more incidents of bleeding and (or) infections than those who were prepossessing an inactive placebo, according to a team reporting Saturday at the annual meeting of the American College of Cardiology, in San Francisco. "We are disenchanted that these results did not show benefits for our patients," study clue author Jane Armitage, a professor at the University of Oxford in England, said in a meeting hearsay release tarika. "Niacin has been used for many years in the belief that it would help patients and prevent heart attacks and stroke, but we now remember that its adverse side effects outweigh the benefits when used with current treatments".

Niacin has covet been used to boost levels of "good" HDL cholesterol and decrease levels of "bad" LDL cholesterol and triglycerides (fats) in the blood in kinfolk at risk for heart disease and stroke. However, niacin also causes a troop of side effects, including flushing of the skin. A upper called laropiprant can reduce the incidence of flushing in people taking niacin. This creative study included patients with narrowing of the arteries.

They received either 2 grams of extended-release niacin with 40 milligrams of laropiprant or matching placebos. All of the patients also took Zocor (simvastatin). The patients from China, the United Kingdom and Scandinavia were followed for an general of almost four years.

Besides showing no profitable effect on heart health outcomes, the team noted that kin taking niacin had about the same amount of heart-related events (13,2 percent) as those who took a placebo a substitute (13,7 percent). Side effects were common. As already reported online Feb 26, 2013 in the European Heart Journal, by the end of the study, 25 percent of patients irresistible niacin and laropiprant had stopped their treatment, compared with 17 percent of the patients taking a placebo.

And "The pre-eminent reason for patients stopping the treatment was because of adverse side effects, such as itching, rashes, flushing, indigestion, diarrhea, diabetes and muscle problems," Armitage said at the while in a newspaper news release. "We found that patients allocated to the experimental treatment were four times more favourite to stop for skin-related reasons, and twice as likely to stop because of gastrointestinal problems or diabetes-related problems". Patients winsome niacin and laropiprant had a more than fourfold increased risk of muscle bother or weakness compared to the placebo group, the team noted.

Did the fault lie with the laropiprant and not niacin? Armitage is doubtful. She mucroniform to a prior trial, called AIM-HIGH, which was discontinued first in 2011 when researchers found no benefit to niacin treatment. At the time, some experts said that the smaller folk in AIM-HIGH masked any sign of benefit, but Armitage said the new trial's much bigger haunt group confirms that niacin probably does not help.

Speaking in February 2013 at the time of the journal's freedom of niacin's safety profile, one US expert was less than impressed by niacin's performance. The annoyance "confirms that, for the present moment, there may be little additional benefit with the use of niacin when patients are well treated with the lipid-lowering statin drugs," said Dr Kevin Marzo, head of cardiology at Winthrop-University Hospital in Mineola, NY. He said that the results of the rejuvenated trial, along with those from a old large study, "now may put the final nail in the coffin on niacin-based strategies to raise HDL and abase cardiovascular events".

Other tried-and-true approaches may work best, Marzo added. "In uniting to statins, our focus should be on continued lifestyle changes such as a Mediterranean diet, complemented with habitually exercise," he said. The US Food and Drug Administration had been waiting on the new examination results to decide whether to approve niacin/laropiprant for use against heart disease. But in December 2012, responding to preparation findings, drug maker Merck said it no longer planned to press for blessing from the FDA and in January 2013

delayed niacin/laropiprant from markets worldwide rxlistbox.